Eli Lilly and Company (LLY)vsVivani Medical Inc. (VANI)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
VANI
Vivani Medical Inc.
$1.18
-7.81%
HEALTHCARE · Cap: $97.45M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
VANI
Avoid16
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : VANI
VANI has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : VANI
The primary concerns for VANI are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while VANI is a value play — different risk/reward profiles.
VANI carries more volatility with a beta of 3.29 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 16/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Vivani Medical Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Vivani Medical Inc. (VANI) is an innovative biotechnology firm dedicated to transforming chronic disease management through its cutting-edge drug delivery technologies. The company develops advanced biocompatible implants designed for sustained medication release, addressing critical health issues such as diabetes and neurological disorders. With a robust product pipeline and a strong intellectual property portfolio, Vivani is well-positioned to meet significant unmet medical needs in the healthcare sector, presenting a compelling investment opportunity for institutional investors seeking exposure to the rapidly evolving biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?